Odile Launay1, Vered Abitbol2, Anne Krivine3, Lilia Ben Slama4, Arnaud Bourreille5, Jean Louis Dupas6, Xavier Hébuterne7, Guillaume Savoye8, Dominique Deplanque9, Yoram Bouhnik10, Anne Laure Pelletier11, Florence Galtier12, David Laharie13, Maria Nachury14, Frank Zerbib15, Mathieu Allez16, Gilles Bommelaer17, Bernard Duclos18, Frederic Lucht19, Marie-Lise Gougeon20, Eric Tartour21, Flore Rozenberg22, Thomas Hanslik23, Laurent Beaugerie24, Fabrice Carrat25. 1. Université Paris Descartes, Sorbonne Paris Cité, Paris, France Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France INSERM, CIC 1417, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France odile.launay@cch.aphp.fr. 2. AP-HP, Hôpital Cochin, Service de gastro-entérologie, Paris, France. 3. AP-HP, Hôpital Cochin, Service de virologie, Paris, France. 4. Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin-Pasteur, Paris, France. 5. CHU Nantes, Hôtel Dieu, Nantes, France. 6. Service d'Hépatogastroentérologie, Hôpital Nord, Amiens, France. 7. Hôpital de l'Archet, Fédération d'Hépatogastroentérologie et de nutrition clinique, Nice, France. 8. Service Hépatogastroentérologie et Nutrition, Hôpital Charles Nicolle, Rouen, France. 9. INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM-CHRU de Lille, CIC 1403, Lille, France. 10. Hôpital Beaujon, Service de Gastroentérologie et Assistance Nutritive, Clichy, France. 11. Service de Gastroentérologie, Hôpital Bichat Claude Bernard, Paris, France. 12. INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France INSERM, CIC de Montpellier, Hôpital Saint Eloi, Montpellier, France. 13. Service d'Hépatogastroentérologie, Hôpital Haut-Lévêque, Pessac, France. 14. Service de Gastroentérologie, CHU Jean Minjoz, Besançon, and Service d'Hépatogastroentérologie, Hôpital Claude Huriez, Lille, France. 15. Service d'Hépato-gastroentérologie, Hôpital Saint-André, Bordeaux, France. 16. Service de Gastroentérologie, AP-HP, Hôpital Saint-Louis, Paris, France. 17. Service de Médecine Digestive et Hépatobiliaire, CHU Estaing, Clermont-Ferrand, France. 18. Hôpitaux Universitaires de Strasbourg, Service d'Hépato gastroentérologie, Hôpital de Hautepierre, INSERM U1113, Strasbourg, France. 19. INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France CHU Saint Etienne, Service des Maladies Infectieuses et tropicales, Saint Etienne, France. 20. INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Antiviral Immunity, Biotherapy and Vaccine Unit, Infection and Epidemiology Department, Institut Pasteur, Paris, France. 21. Université Paris Descartes, Sorbonne Paris Cité, Paris, France INSERM, F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Paris, France Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, INSERM, UMR_S 970, PARCC, Paris, France. 22. Université Paris Descartes, Sorbonne Paris Cité, Paris, France AP-HP, Hôpital Cochin, Service de virologie, Paris, France. 23. Service de médecine interne, AP-HP; Hôpital Ambroise Paré, Université de Versailles Saint-Quentin-en-Yvelines, Boulogne-Billancourt, France. 24. Service de Gastroentérologie, AP-HP, Hôpital Saint-Antoine et INSERM/UMRS 7203, UPMC Université de Paris VI, Paris, France. 25. Département de santé publique, AP-HP, Hôpital Saint-Antoine, Paris, France Université Pierre et Marie Curie, UMR-S 1136, Paris, France INSERM, U1136, Paris, France.
Abstract
BACKGROUND AND AIMS: Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults. METHODS: A multicentre prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine in the years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres were assessed before and 3 weeks and 6 months after vaccination. RESULTS: At inclusion, 31 patients were receiving no IS treatment (Group A), 77 were receiving IS treatment without anti-TNF (Group B) and 117 were receiving anti-tumour necrosis factor (TNF) treatment with or without IS treatment (Group C). Three weeks after the first vaccination, rates of seroprotection were 77, 75 and 66% for strain A/H1N12007 (p = 0.35), 77, 68 and 52% for strain A/H3N2 (p = 0.014) and 97, 96 and 95% for strain B (p = 0.99) in Groups A, B and C, respectively. Seroconversion rates for A/H1N12007 (67, 64 and 54%; p = 0.28), A/H3N2 (63, 50 and 41%; p = 0.074) and strain B (63, 76 and 60%; p = 0.078) were not significantly different among treatment groups. At 6 months after vaccination, seroprotection rates were lower in Group C compared with Groups A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores was detected. CONCLUSIONS: Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF treatment. ClinicalTrials.gov, number NCT01022749.
BACKGROUND AND AIMS: Data on the efficacy and safety of seasonal influenza vaccines in patients with inflammatory bowel disease (IBD) remain scarce. The aim of the study was to evaluate the impact of immunosuppressive (IS) therapeutics on serological response to 2-year influenza vaccination in IBD adults. METHODS: A multicentre prospective study performed in 255 IBD adults (18-64 years) receiving the trivalent influenza vaccine in the years 2009-2010 and 2010-2011. Haemagglutination inhibition (HI) titres were assessed before and 3 weeks and 6 months after vaccination. RESULTS: At inclusion, 31 patients were receiving no IS treatment (Group A), 77 were receiving IS treatment without anti-TNF (Group B) and 117 were receiving anti-tumour necrosis factor (TNF) treatment with or without IS treatment (Group C). Three weeks after the first vaccination, rates of seroprotection were 77, 75 and 66% for strain A/H1N12007 (p = 0.35), 77, 68 and 52% for strain A/H3N2 (p = 0.014) and 97, 96 and 95% for strain B (p = 0.99) in Groups A, B and C, respectively. Seroconversion rates for A/H1N12007 (67, 64 and 54%; p = 0.28), A/H3N2 (63, 50 and 41%; p = 0.074) and strain B (63, 76 and 60%; p = 0.078) were not significantly different among treatment groups. At 6 months after vaccination, seroprotection rates were lower in Group C compared with Groups A and B. Comparable results were observed for the second year of vaccination. No impact on Harvey-Bradshaw and Mayo scores was detected. CONCLUSIONS: Influenza vaccine yielded high seroprotection rates in IBD patients. Persistence of seroprotection was lower in patients with anti-TNF treatment. ClinicalTrials.gov, number NCT01022749.
Authors: Dawn B Beaulieu; Ashwin N Ananthakrishnan; Christopher Martin; Russell D Cohen; Sunanda V Kane; Uma Mahadevan Journal: Clin Gastroenterol Hepatol Date: 2017-09-01 Impact factor: 11.382
Authors: Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade Journal: J Cutan Med Surg Date: 2018-11-21 Impact factor: 2.092
Authors: Sandra Maria Barbalho; Julia Novaes Matias; Uri Adrian Prync Flato; Joao Paulo Galletti Pilon; Piero Bitelli; Marcos Alberto Pagani Junior; Antonelly Cassio Alves de Carvalho; Jesselina Francisco Dos Santos Haber; Carlos Henrique Bertoni Reis; Ricardo de Alvares Goulart Journal: Gastroenterology Res Date: 2021-02-19
Authors: Jennifer L Jones; Frances Tse; Matthew W Carroll; Jennifer C deBruyn; Shelly A McNeil; Anne Pham-Huy; Cynthia H Seow; Lisa L Barrett; Talat Bessissow; Nicholas Carman; Gil Y Melmed; Otto G Vanderkooi; John K Marshall; Eric I Benchimol Journal: J Can Assoc Gastroenterol Date: 2021-07-29